Clinical Trial Update: A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 study of FF-10501-01 in combination with azacitidine for myelodysplastic syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• FF-10501-01

Snippet

Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. | Conditions: Myelodysplastic Syndrome (MDS) | Phase 2 | Status: WITHDRAWN